About Intelligent Bio Solutions Inc.
https://gbs.incIntelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva.
CEO
Harry Simeonidis
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-12-16 | Reverse | 1:10 |
| 2024-01-29 | Reverse | 1:12 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C-
Price Target
Institutional Ownership
ALYESKA INVESTMENT GROUP, L.P.
Shares:673.49K
Value:$10.55M
ADAR1 CAPITAL MANAGEMENT, LLC
Shares:426.43K
Value:$6.68M
VANGUARD GROUP INC
Shares:97.69K
Value:$1.53M
Summary
Showing Top 3 of 14
About Intelligent Bio Solutions Inc.
https://gbs.incIntelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $1.11M ▲ | $3.52M ▲ | $-2.98M ▲ | -268.3% ▲ | $-3.5 ▲ | $-2.68M ▲ |
| Q4-2025 | $843.88K ▲ | $3.44M ▲ | $-3.09M ▼ | -366.13% ▼ | $-4.4 | $-2.79M ▼ |
| Q3-2025 | $728.87K ▲ | $2.89M ▲ | $-2.54M ▼ | -348.97% ▲ | $-4.4 ▲ | $-2.23M ▼ |
| Q2-2025 | $607.49K ▼ | $2.49M ▼ | $-2.25M ▲ | -370.29% ▼ | $-5 ▲ | $-1.94M ▲ |
| Q1-2025 | $872.29K | $3.07M | $-2.69M | -307.88% | $-7 | $-2.37M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $1.66M ▲ | $10.04M ▲ | $6.61M ▲ | $3.62M ▲ |
| Q4-2025 | $1.02M ▼ | $8.25M ▼ | $5.44M ▲ | $3M ▼ |
| Q3-2025 | $2.81M ▲ | $9.58M ▲ | $4.64M ▲ | $5.11M ▲ |
| Q2-2025 | $2.24M ▼ | $8.68M ▼ | $4.48M ▼ | $4.37M ▼ |
| Q1-2025 | $6.42M | $13.78M | $5.6M | $8.33M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-2.98M ▲ | $-2.85M ▼ | $-70.4K ▲ | $3.56M ▲ | $640.2K ▲ | $-2.92M ▼ |
| Q4-2025 | $-3.1M ▼ | $-2.21M ▲ | $-208.52K ▼ | $602K ▼ | $-1.79M ▼ | $-2.42M ▲ |
| Q3-2025 | $-2.55M ▼ | $-2.76M ▼ | $-14.38K ▼ | $3.32M ▲ | $564.9K ▲ | $-2.77M ▼ |
| Q2-2025 | $-2.25M ▲ | $-2.32M ▲ | $-8.94K ▼ | $631.74K ▲ | $-1.75M ▲ | $-2.33M ▲ |
| Q1-2025 | $-2.69M | $-2.39M | $0 | $42.45K | $-2.31M | $-2.39M |
Revenue by Products
| Product | Q1-2025 | Q2-2025 | Q3-2025 | Q4-2025 |
|---|---|---|---|---|
 Other Sales | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2025 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 AUSTRALIA | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Other Country | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Harry Simeonidis
Compensation Summary
(Year 2025)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-12-16 | Reverse | 1:10 |
| 2024-01-29 | Reverse | 1:12 |
ETFs Holding This Stock
Summary
Showing Top 1 of 1
Ratings Snapshot
Rating : C-
Price Target
Institutional Ownership
ALYESKA INVESTMENT GROUP, L.P.
Shares:673.49K
Value:$10.55M
ADAR1 CAPITAL MANAGEMENT, LLC
Shares:426.43K
Value:$6.68M
VANGUARD GROUP INC
Shares:97.69K
Value:$1.53M
Summary
Showing Top 3 of 14